Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Fig. 4

High serum ADAM12 levels associate with unfavorable outcome in mesenchymal tumors. Expression of ADAM12 was stratified by molecular subtypes in the AMC-AJCCII-90 dataset, N = 67. Significance is tested by unpaired two tailed Student’s t-test (A). Absolute serum levels of ADAM12 in CAIRO2 FFPE samples stratified by molecular subtypes. N = 146 (B). Serum levels of ADAM12 were dichotomized by ADAM12 levels (222 pg/mL). Survival analysis by Kaplan-Meier is shown for epithelial (CMS2/3) tumors (C) and mesenchymal (CMS4) tumors (D)

Back to article page